Difference between revisions of "Immune effector cells toxicity management"
Jump to navigation
Jump to search
m (→Guidelines) |
m (→EBMT/JACIE/EHA) |
||
| Line 18: | Line 18: | ||
*'''2019:''' Lee et al. [https://doi.org/10.1016/j.bbmt.2018.12.758 ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells] | *'''2019:''' Lee et al. [https://doi.org/10.1016/j.bbmt.2018.12.758 ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells] | ||
==EBMT/JACIE/EHA== | ==EBMT/JACIE/EHA== | ||
| − | *'''2022:''' Hayden et al. [https://doi.org/10.1016/j.annonc.2021.12.003 Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)] | + | *'''2022:''' Hayden et al. [https://doi.org/10.1016/j.annonc.2021.12.003 Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)] [https://pubmed.ncbi.nlm.nih.gov/34923107/ PubMed] |
| + | =="How I Treat"== | ||
| + | *'''2023:''' Gutierrez et al. [https://doi.org/10.1182/blood.2022017579 How I approach optimization of patients at risk of cardiac and pulmonary complications after CAR T-cell therapy] [https://pubmed.ncbi.nlm.nih.gov/36827628/ PubMed] | ||
| + | *'''2023:''' Jain et al. [https://doi.org/10.1182/blood.2022017414 How I treat refractory CRS and ICANS after CAR T-cell therapy] [https://pubmed.ncbi.nlm.nih.gov/36989488/ PubMed] | ||
| + | *'''2023:''' Jain et al. [https://doi.org/10.1182/blood.2022017415 How I treat cytopenias after CAR T-cell therapy] [https://pubmed.ncbi.nlm.nih.gov/36800563/ PubMed] | ||
| + | *'''2023:''' Santomasso et al. [https://doi.org/10.1182/blood.2022017604 How I treat unique and difficult-to-manage cases of CAR T-cell therapy-associated neurotoxicity] [https://pubmed.ncbi.nlm.nih.gov/36877916/ PubMed] | ||
| + | |||
==SITC== | ==SITC== | ||
*'''2020:''' Maus et al. [http://dx.doi.org/10.1136/jitc-2020-001511 Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events] | *'''2020:''' Maus et al. [http://dx.doi.org/10.1136/jitc-2020-001511 Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events] | ||
Revision as of 00:22, 14 June 2023
| Page co-editor | Page co-editor | ||
|---|---|---|---|
 |
Leyre Zubiri, MD, PhD Massachusetts General Hospital Boston, MA |
 |
Matthew Hadfield, DO Lifespan/Brown University Providence, RI |
The purpose of this page is to address the management of toxicity from BiTE and immune effector cell (IEC) therapy, notably CAR-T. There is a separate page for the management of immune checkpoint inhibitor (ICI) toxicities, available here.
Guidelines
ASCO
- 2021: Santomasso et al. Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline
ASTCT
- 2019: Lee et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
EBMT/JACIE/EHA
- 2022: Hayden et al. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA) PubMed
"How I Treat"
- 2023: Gutierrez et al. How I approach optimization of patients at risk of cardiac and pulmonary complications after CAR T-cell therapy PubMed
- 2023: Jain et al. How I treat refractory CRS and ICANS after CAR T-cell therapy PubMed
- 2023: Jain et al. How I treat cytopenias after CAR T-cell therapy PubMed
- 2023: Santomasso et al. How I treat unique and difficult-to-manage cases of CAR T-cell therapy-associated neurotoxicity PubMed
SITC
- 2020: Maus et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events